COVID-19 clinical course and blood groups: Turkish population-based study

Ankara Onkoloji Eğitim ve Araştırma Hastanesi Hematoloji ve Kemik İliği Nakil Merkezi Anabilim Dalı, Ankara, Türkiye 2 Strateji Geliştirme Daire Başkanlığı, Türkiye Cumhuriyeti, Sağlık Bakanlığı, Ankara, Türkiye 3 Hematoloji Anabilim Dalı, Kayseri Şehir Hastanesi, Kayseri, Türkiye 4 Bozyaka Eğitim ve Araştırma Hastanesi Hematoloji Anabilim Dalı, İzmir, Türkiye 5 Hematoloji Anabilim Dalı, Tıp Fakültesi, Selçuk Üniversitesi, Konya, Türkiye 6 Sakarya Üniversitesi Tıp Fakültesi Hematoloji Anabilim Dalı, Sakarya, Türkiye 7 İstanbul Eğitim ve Araştırma Hastanesi Hematoloji Anabilim Dalı, İstanbul, Türkiye 8 İnönü Üniversitesi Tıp Fakültesi Hematoloji Anabilim Dalı, Malatya, Türkiye 9 Keçiören Eğitim ve Araştırma Hastanesi İç Hastalıkları Anabilim Dalı, Ankara, Türkiye 10Namık Kemal Üniversitesi Tıp Fakültesi Hematoloji Anabilim Dalı, Tekirdağ, Türkiye 11Ankara İl Sağlık Müdürlüğü, Ankara, Türkiye 12Sağlık Bilgi Sistemleri Genel Müdürlüğü, Sağlık Bakanlığı, Türkiye Cumhuriyeti, Ankara, Türkiye 13Kamu Hastaneleri Genel Müdürlüğü, Sağlık Bakanlığı, Türkiye Cumhuriyeti, Ankara, Türkiye 14Sağlık Bakan Yardımcısı, Türkiye Cumhuriyeti, Ankara, Türkiye

PDF

___

1. Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus 2020; 12 (3): e7423. doi:10.7759/cureus.7423
2. Li Q, Guan X, Wu P, Wang X, Zhou L et al. Early TRANSMISSION DYNAMICS in Wuhan, China, of novel coronavirus-infected pneumonia. New England Journal of Medicine. 2020; 382 (13): 1199-1207. doi:10.1056/NEJMoa2001316
3. Zhu N, Zhang D, Wang W, Li X, Yang B et al. China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020; 382 (8): 727-733. doi:10.1056/NEJMoa2001017
4. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomedica 2020; 91 (1): 157-160. doi: 10.23750/abm. v91i1.9397
5. Franchini M, Favaloro EJ, Targher G, Lippi G. ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Critical Reviews in Clinical Laboratory Sciences 2012; 49: 137- 149. doi:10.3109/10408363.2012.708647
6. Weisbrod AB, Nilubol N, Weinstein LS, Simonds WF, Libutti SK et al. Association of type - O blood with neuroendocrine tumors in multiple endocrine neoplasia type 1. Journal of Clinical Endocrinology and Metabolism. 2012; 98: 109-114. doi:10.1210/jc.2012-2781
7. Greenwell P. Blood group antigens: Molecules seeking a function? Glycoconjugate Journal 1997; 14: 159-173. doi:10.1023/a:1018581503164
8. Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al-Nasser AD. SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens 2020; 9: 231. doi:10.3390/pathogens9030231
9. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 181 (2): 281-292. doi:10.1016/j. cell.2020.02.058
10. Li G, Fan Y, Lai Y, Han T, Li Z et al. Coronavirus infections and immune responses. Journal of Medical Virology 2020; 92: 424- 432. doi:10.1002/jmv.25685
11. Gralinski LE, Menachery VD. Return of the coronavirus: 2019- nCoV. Viruses 2020; 12 (2): 135. doi:10.3390/v12020135
12. Zhou P, Yang X., Wang XG, Hu B, Zhang L et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270-273. doi:10.1038/s41586-020- 2012-7
13. Guillon P, Clement M, Sebille V, Rivain JG, Chou CF et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by antihisto-blood group antibodies. Glycobiology 2008; 18 (12): 1085-1093. doi:10.1093/glycob/cwn093
14. Kumar S, Maurya VK, Prasad AK, Bhatt MLB, Saxena SK. Structural, glycosylation and 206 antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). Virus disease 2020; 31: 13-21. doi:10.1007/ s13337-020-00571-5
15. Zaidi FZ, Zaidi ARZ, Abdullah SM, Zaidi SZA. COVID-19 and the ABO blood group connection. Transfusion Apheresis Science 2020; 59 (5): 102838. doi:10.1016/j.transci.2020.102838
16. Li J, Wang X, Chen J, Cai Y, Deng A et al. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. British Journal of Haematology 2020; 190 (1): 24-27. doi:10.1111/ bjh.16797
17. Ray JG, Schull MJ, Vermeulen MJ, Park AL. Association between ABO and Rh blood groups and SARS-CoV-2 infection or severe COVID-19 illness: a population-based cohort study. Annals of Internal Medicine 2021; 174b(3): 308- 315. doi:10.7326/M20-4511
18. Barnkob MB, Pottegård A, Støvring H, Haunstrup TM, Homburg K et al. Reduced prevalence of SARS-CoV-2 infection in ABO blood group O. Blood Advances 2020; 4 (20): 4990-4993. doi:10.1182/bloodadvances.2020002657
19. Padhi S, Suvankar S, Dash D, Panda VK, Pati A et al. ABO blood group system is associated with COVID-19 mortality: An epidemiological investigation in the Indian population. Transfusion Clinique et Biologique 2020; 27 (4): 253-258. doi:10.1016/j.tracli.2020.08.009
20. Solmaz İ, Araç S. ABO blood groups in COVID-19 patients; Cross-sectional study. International Journal of Clinical Practice 2021; 75 (4): e13927. doi:10.1111/ijcp.13927
21. Göker H, Aladağ Karakulak E, Demiroğlu H, Ayaz Ceylan ÇM, Büyükaşik Y et al. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. Turkish Journal of Medical Sciences 2020; 50 (4): 679-683. doi:10.3906/ sag-2005-395
22. Arendrup M, Hansen JE, Clausen H, Nielsen C, Mathiesen LR et al. Antibody to histo-blood group A antigen neutralizes HIV produced by lymphocytes from blood group A donors but not from blood group B or O donors. AIDS 1991; 5: 441-444. doi:10.1097/00002030-199104000-00014
23. Neil SJ, McKnight A, Gustafsson K, Weiss RA. HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivation. Blood 2005; 105: 4693-4699. doi:10.1182/blood-2004-11-4267
24. Preece AF, Strahan KM, Devitt J, Yamamoto F, Gustafsson K. Expression of ABO or related antigenic carbohydrates on viral envelopes leads to neutralization in the presence of serum containing specific natural antibodies and complement. Blood 2002; 99: 2477-2482. doi:10.1182/blood.v99.7.2477
25. Cheng Y, Cheng G, Chui CH, Lau FY, Chan PK et al. ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA 2005; 293 (12): 1450-1451. doi:10.1001/ jama.293.12.1450-c
26. Chen J, Subbarao K. The immunobiology of SARS. Annual Review of Immunology 2007; 25: 443-472. doi:10.1146/ annurev.immunol.25.022106.141706
27. Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. American Journal of Pathology 2007; 170:1136-1147. doi:10.2353/ajpath.2007.061088
28. Stager S, Alexander J, Kirby AC, Botto M, Rooijen NV et al. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nature Medicine 2003; 9: 1287-1292. doi:10.1038/nm933
29. Durrbach A, Baple E, Preece AF, Charpentier B, Gustafsson K. Virus recognition by specific natural antibodies and complement results in MHC I cross-presentation. European Journal of Immunology 2007; 37 (5): 1254-1265. doi:10.1002/ eji.200636129
30. de França ND, Poli MC, Ramos PG, Borsoi CS, Colella R. Titers of ABO antibodies in group O blood donors. Revista Brasileira de Hematologia e Hemoterapia 2011; 33 (4): 259-62. doi:10.5581/1516-8484.20110073
31. Tendulkar AA, Jain PA, Velaye S. Antibody titers in group O platelet donors. Asian Journal of Transfusion Sciences 2017; 11: 22-27. doi:10.4103/0973-6247.200765
32. Zhao J, Yang Y, Huang H, Li D, Gu D et al. Relationship between the ABO blood group and the COVID-19 susceptibility. MedRxiv 2020; 03.11.20031096. doi: 10.1101/2020.03.11.20031096
33. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A et al. Genomewide Association Study of Severe COVID-19 with Respiratory Failure. New England Journal of Medicine. 2020; 383(16): 1522-1534. doi:10.1056/NEJMoa2020283